deltatrials
Completed PHASE4 INTERVENTIONAL 5-arm NCT02184624

Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices

An Open-label Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: GlaxoSmithKline

Conditions Pulmonary Disease, Chronic Obstructive
Interventions BREEZEHALER DISKUS/ACCUHALER ELLIPTA HANDIHALER MDI TURBUHALER
Updated 10 times since 2017 Last updated: Apr 25, 2017 Started: Aug 28, 2014 Primary completion: Jul 31, 2015 Completion: Jul 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~May 2017 · 4 months · monthly snapshotCompleted~May 2017 – ~Jul 2017 · 2 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotCompleted~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotCompleted~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 9 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE4

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE4

▶ Show 5 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE4

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  3. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE4

  4. May 2017 — Jul 2017 [monthly]

    Completed PHASE4

  5. Jan 2017 — May 2017 [monthly]

    Completed PHASE4

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations